Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
Belize, a small country located in Central America, has a developing pharmaceutical market that is influenced by various factors.
Customer preferences: Belizeans generally prefer generic drugs due to their affordability. However, there is a growing demand for branded drugs, especially among the middle and upper classes. This demand is driven by the perception that branded drugs are of higher quality and more effective than their generic counterparts.
Trends in the market: The pharmaceutical market in Belize is heavily regulated by the government. The government controls the importation, distribution, and pricing of pharmaceutical products. The country has a limited manufacturing capacity, and most of the drugs are imported. The market is dominated by multinational companies, which account for a significant share of the market. However, there is a growing trend towards local manufacturing, with the government providing incentives to encourage local production.
Local special circumstances: Belize has a small population, which limits the size of the pharmaceutical market. The country also has a high poverty rate, which affects the affordability of drugs for many Belizeans. The government has implemented various policies to improve access to healthcare, including the provision of free drugs to certain groups of people.
Underlying macroeconomic factors: Belize has a small economy that is heavily dependent on tourism. The COVID-19 pandemic has had a significant impact on the economy, with a sharp decline in tourism revenues. This has affected the pharmaceutical market, with reduced demand for drugs due to the drop in disposable income. The government has implemented various measures to mitigate the impact of the pandemic, including the provision of subsidies to businesses and individuals.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)